| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/07853890008998838 |
| P698 | PubMed publication ID | 11127936 |
| P2093 | author name string | Vanhanen H | |
| Strandberg TE | |||
| Tikkanen MJ | |||
| P2860 | cites work | State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action | Q33752650 |
| Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness | Q33767970 | ||
| Inflammation markers and coronary heart disease | Q33770537 | ||
| Non-lipid-related effects of statins | Q33924588 | ||
| C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study | Q40828366 | ||
| Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia | Q41898174 | ||
| Novel inflammatory markers of coronary risk: theory versus practice. | Q54332281 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 579-583 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | Annals of Medicine | Q4767853 |
| P1476 | title | Associations between change in C-reactive protein and serum lipids during statin treatment. | |
| P478 | volume | 32 |
| Q34856914 | A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis |
| Q63385321 | Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide |
| Q34401802 | Diet and drug therapy: a dynamic duo for reducing coronary heart disease risk |
| Q44123481 | Effect of alcohol consumption on endothelial function in men with coronary artery disease |
| Q44160615 | Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease |
| Q52886658 | Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. |
| Q38454661 | Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients |
| Q34428150 | Inflammatory pathways in atherosclerosis and acute coronary syndromes |
| Q40551953 | Marked reduction in serum high-density lipoprotein cholesterol concentrations in a woman with acute inflammation due to diabetic gangrene |
| Q58314403 | Markers of the Acute Phase Response in Cardiovascular Disease: An Update |
| Q44213804 | Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study |
| Q44524789 | Non-lipid effects of statins: myth or fact? |
| Q35574960 | Pharmacotherapy for dyslipidaemia – current therapies and future agents |
| Q37962460 | Role of C-reactive protein when prescribing a statin |
| Q35077911 | Sensitive markers of inflammation make it possible to study the chronic process: the rise of interest in low levels of C-reactive protein |
| Q46784247 | Short-term changes in inflammatory response protein (hsCRP) do not parallel with changes in coronary vasoreactivity in obese men. |
| Q79398950 | Statins inhibit lymphocyte homing to peripheral lymph nodes |
| Q44249465 | Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus |
| Q56970796 | Vascular function in patients with end-stage renal disease and/or coronary artery disease: A cardiac magnetic resonance imaging study |
Search more.